NCT03803761 2023-09-25
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
Clinical Trials
25 trialsNCT05222165 2023-02-23
NEWEL
Helsinn Healthcare SA
Phase 1/2 Withdrawn
NCT05218408 2023-02-16
CYNK001GBM02
Celularity Incorporated
Phase 1/2 Withdrawn
NCT03649464 2022-10-07
Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants
Oblato, Inc.
Phase 1/2 Withdrawn
NCT04315246 2022-07-15
177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)
Y-mAbs Therapeutics
Phase 1/2 Withdrawn
NCT04512261 2022-07-01
TOPAZ
Cedars-Sinai Medical Center
Phase 1/2 Withdrawn
NCT04065087 2022-03-17
Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma
Genexine, Inc.
Phase 1/2 Withdrawn
NCT03923257 2021-06-08
Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
University of Iowa
Phase 1/2 Withdrawn
NCT02038699 2021-04-30
A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer
Jazz Pharmaceuticals
Phase 1/2 Withdrawn
NCT02575261 2020-07-16
CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients
Fuda Cancer Hospital, Guangzhou
Phase 1/2 Withdrawn
NCT03252171 2020-07-16
CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients
Fuda Cancer Hospital, Guangzhou
Phase 1/2 Withdrawn
NCT04406610 2020-07-16
CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients
Fuda Cancer Hospital, Guangzhou
Phase 1/2 Withdrawn
NCT02713984 2020-03-19
A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Southwest Hospital, China
Phase 1/2 Withdrawn
NCT03973879 2020-02-11
Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma
Duke University
Phase 1/2 Withdrawn
NCT00984438 2019-11-25
Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme
University of Cincinnati
Phase 1/2 Withdrawn
NCT00977795 2019-09-10
A Study of the Specificity and Sensitivity of 5-ALA Fluorescence in Malignant Brain Tumors
Endeavor Health
Phase 1/2 Withdrawn
NCT03297463 2018-08-01
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
Masonic Cancer Center, University of Minnesota
Phase 1/2 Withdrawn
NCT01740570 2018-01-19
Phase I/II Cabazitaxel for Recurrent Malignant Glioma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT00397501 2017-04-21
BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain
OHSU Knight Cancer Institute
Phase 1/2 Withdrawn
NCT02065466 2016-04-21
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
University of Arizona
Phase 1/2 Withdrawn
NCT02521090 2016-02-15
EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Withdrawn
NCT01174537 2015-06-11
New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma
Hadassah Medical Organization
Phase 1/2 Withdrawn
NCT00378235 2014-11-13
Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma
INSYS Therapeutics Inc
Phase 1/2 Withdrawn
NCT00021307 2013-07-11
Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme
Fox Chase Cancer Center
Phase 1/2 Withdrawn
NCT00053040 2010-09-24
Immunotoxin Therapy in Treating Children With Recurrent Malignant Gliomas
Pediatric Brain Tumor Consortium
Phase 1/2 Withdrawn